News and Analysis
Innovation, Technology, and IP News
Feed tagged as "pharma":
In a groundbreaking legal development, Eli Lilly has secured a remarkable victory in a high-stakes patent battle that has sent shockwaves... Read More »
In the intricate world of pharmaceuticals, where innovation meets regulation, ANDA litigation stands as a pivotal battleground... Read More »
In the realm of pharmaceuticals, the approval process for generic and brand-name drugs holds significant importance. The Hatch-Waxman Act, ... Read More »
British drugmaker GlaxoSmithKline (GSK) has taken American pharmaceutical giant Pfizer to court, alleging a violation of its patent rights ... Read More »
When it comes to generic medications, the Abbreviated New Drug Application (ANDA) process plays a crucial role in bringing affordable... Read More »
The landscape of patent litigation is ever-evolving, and the first half of 2023 has been no exception. The dynamics of patent litigation are... Read More »
When it comes to preparing an Abbreviated New Drug Application (ANDA), there are several common pitfalls that applicants often encounter... Read More »
The Abbreviated New Drug Application (ANDA) process plays a vital role in the pharmaceutical industry, enabling generic drug manufacturers ... Read More »
Promosome LLC, a biotech firm represented by law firm Susman Godfrey, has just filed a patent infringement lawsuits against Moderna... Read More »
The Hatch-Waxman Act, officially known as the Drug Price Competition and Patent Term Restoration Act, revolutionized the pharmaceutical... Read More »
In the world of pharmaceuticals, the Abbreviated New Drug Application (ANDA) process plays a critical role in the approval and market... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed... Read More »
In late August, we published our third annual ANDA Litigation Intelligence Report, covering important statistics and evaluating all stakeholders in ... Read More »
Last August, we published our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape and focused on... Read More »
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More »
In late August we released our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape by providing... Read More »
Two days ago, the companies that joined forces in order to develop the first Covid vaccine that got approval for emergency use by FDA... Read More »
This morning we released our third annual ANDA Litigation Intelligence Report. The report covers high-level statistics related to Hatch-Waxman... Read More »
The FDA evaluates the generic versions of a drug and approves them only if studies show that it is bioequivalent with the... Read More »
In early 1983, Bolar Pharmaceutical Inc. wanted to bring a generic version of the Dalmane drug, a sleeping pill, to the market. At that... Read More »